


Abstract

Validation of an In Vitro Fermentation Model of Colonic Gas Production [†]

Catriona L. Thomson, Ada L. Garcia  and Christine A. Edwards * 

Human Nutrition, School of Medicine, Dentistry and Nursing, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G31 2ER, UK; c.thomson.5@research.gla.ac.uk (C.L.T.); ada.garcia@glasgow.ac.uk (A.L.G.)

* Correspondence: christine.edwards@glasgow.ac.uk

[†] Presented at the 14th European Nutrition Conference FENS 2023, Belgrade, Serbia, 14–17 November 2023.

Abstract: Background: The rapid production of gas during the colonic fermentation of highly soluble fermentable fibres may cause unpleasant gastrointestinal symptoms. In vivo feeding studies are often used to assess symptomatic response to fibres; however, in vitro fermentation studies are quicker, cheaper, and more reproducible. The aim of this study was to validate an in vitro colonic fermentation model of gas production against in vivo experiences of symptoms following inulin consumption. Methods: Healthy volunteers (n = 21, 18–65 y/o, M/F) provided a stool sample used to inoculate an in vitro colonic fermentation model. Fermentation bottles containing faecal slurry, a fermentation medium, and a fibre substrate (inulin) were incubated at 37 °C for 24 h in a shaking water bath. The total gas production (mL) over 24 h (minus control) was measured. Each stool donor added 15 g inulin to a low-fibre diet and recorded experiences of gastrointestinal symptoms for 48h. In vitro gas production and in vivo symptom experience were compared for each donor following tertile classification. Low in vitro gas production was classed as <45mL (<1st quartile of dataset), medium as 45–78 mL (1st quartile–3rd quartile), and high as >78 mL (>3rd quartile). In vivo symptom response was classed as low if symptoms were mild and/or short-lived (<1 h duration); medium if moderate and/or prolonged (1 h); and high when abdominal pain or multiple prolonged (3 h) symptoms occurred. Results: In vitro gas production was high in six cases (29%); medium in ten (48%); and low in five (24%). Symptom experience was high in seven cases (33%); medium in five (24%); and low in nine (43%). The same classification occurred in 57% of cases and classification into adjacent categories occurred in 43%; no complete misclassification occurred. Agreement between the methods was fair: weighted kappa = 0.378 ($p < 0.01$). Discussion: The level of agreement between the in vitro model of gas production and in vivo symptom reports, and the absence of any cases of complete misclassification, is promising. This simple in vitro batch-fermentation model may be used in future to screen fibres for their potential impact on gastrointestinal symptoms. This will help develop strategies to increase fibre consumption generally and optimise their use in food reformulation.

Keywords: dietary fibre; in vitro fermentation; gastrointestinal symptoms



Citation: Thomson, C.L.; Garcia, A.L.; Edwards, C.A. Validation of an In Vitro Fermentation Model of Colonic Gas Production. *Proceedings* **2023**, *91*, 65. <https://doi.org/10.3390/proceedings2023091065>

Academic Editors: Sladjana Sobajic and Philip Calder

Published: 21 November 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Author Contributions: C.L.T., A.L.G. and C.A.E. designed the study and wrote the manuscript, C.L.T. conducted the study and statistical analysis. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by a UKRI-BBSRC CTP PhD studentship grant in collaboration with Mondelez International (grant award number: 2294514).

Institutional Review Board Statement: This study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the University of Glasgow, College of Medical, Veterinary and Life Sciences (project number: 200210043; approval date: 5 January 2022).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: Data available upon reasonable request from the corresponding author.

Conflicts of Interest: C.L.T. is a PhD student funded by the UKRI-BBSRC CTP programme in partnership with Mondelez International.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.